newsfilter
← Latest News
Business Wire·

MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence.